First in Human Single Ascending Dose Study of MOR107

Summary

This is the first in human study of MOR107. It is a 2 part, single centre, double-blind, randomised, placebo-controlled study in healthy male subjects. Part 1 is a single ascending dose study, and Part 2 is a parallel group, dose range finding study in healthy male subjects on a low sodium diet.

Timeline

Start

2017-02-16

Primary completion

2017-03-23

Completion

2017-03-23

Outcome

Outcome not reported

Stopped: “Part 1 completed successfully. Part 2 not conducted.”

Drugs

Indications

No indication recorded.